Stay updated on LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.

Latest updates to the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version tag v3.1.0.SummaryDifference3%

- Check29 days agoChange DetectedUpdated the page from revision v3.0.2 to v3.1.0, signaling a new release version.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page revision updates from v3.0.1 to v3.0.2, indicating a new release; the 'Back to Top' link has been removed, with no other substantive content changes detected.SummaryDifference0.2%

- Check51 days agoChange DetectedThe web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check58 days agoChange DetectedThe web page has updated the facility name and location details, specifically changing from 'Gent, Belgium' to 'Ghent, Belgium'. Additionally, there are updates to the drug names listed, with 'durvalumab' being retained and 'LY3022855' and 'tremelimumab' added.SummaryDifference1%

- Check72 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.